Fms-like tyrosine kinase 3 ligand (Flt3L) plays an important role in development and activation of dendritic cells (DCs) and natural killer cells (NK). It has been shown that administration of either tumor cells transfected in vitro with Flt3L vectors or soluble Flt3L fusion protein in a high dose can enhance host antitumor immunity in animal model systems. In this study, we developed a recombinant defective adenovirus with an insert of gene encoding extracellular domain of mouse Flt3L (Ad-mFlt3L) under control of cytomegalovirus promoter and investigated its biological efficacy in eliciting tumor-specific immune response against hepatocellular carcinoma in mouse hepatoma model. The constructed Ad-mFlt3L efficiently infected hepa 1-6 hepatoma cells both in vitro and in vivo, leading to a high production of mFlt3L proteins in association with accumulation of DCsNK cells and lymphocytes in local tumor tissues. Tumor cells infected with Ad-mFlt3L lost tumorigenicity and became more immunogenic in syngeniec animal models. Intratumoral injection of Ad-mFlt3L (10 9 expression-forming unit) Â 3 significantly inhibited tumor growth with elicitation of long-lasting antitumor immunity, which is both preventive and curative. The tumor-specific immunity can be partially abrogated by depletion of either CD3 þ CD4 þ T cells or NK cells and can be also re-established in naïve animals by adoptive transfer of splenocytes from treated mice. The results suggest that adenovirus-mediated Flt3L gene therapy may provide a useful strategy for treatment of cancers.
T he FLT3 ligand (Flt3L) is a recently identified cell surface molecule that plays an important role in the differentiation and maturation of early murine and human hematopoietic precursor/stem cells. [1] [2] [3] A unique biological function of Flt3L is its ability to induce a striking time-dependent and reversible accumulation of functional dendritic cells (DC) in lymphoid and nonlymphoid tissues, which is critical for elicitation of host immune responses mediated by immune cells and antibodies. [4] [5] [6] Moreover, Flt3L also stimulates activation of NK cells and increases the number of functionally mature NK cells in vivo. [7] [8] [9] Since both DCs and NK cells are key elements in induction of host immune responses, it is reasonable that systemic administration of Flt3L could induce antitumor immune responses that protect against tumor challenges and mediate the regression of established tumors. 10, 11 However, it has been shown that antitumor immunity elicited by administration of Flt3L protein in multiple doses has a limited efficacy to protect host from tumor cell challenge and can inhibit tumor growth only in the animals with relatively small tumor burdens. 12 Administration of either soluble Flt3L protein or tumor cells modified in vitro with Flt3L gene and expressing Flt3L molecules on cell surfaces is unable to induce functional antitumor immunity and, in a few experiments, only cause transient tumor regression, especially in poorly immunogenic tumor models. These treated animals usually developed recurrent tumors after the termination of treatment. 13 Since a short half-time in blood stream and a low accumulation in tumor tissues of soluble Flt3L fusion protein in vivo by their nonspecific binding to the receptors were widely expressed in various tissues, it has been suggested that Flt3L gene therapy may induce more potent antitumor immune response than immunotherapy with soluble Flt3L proteins.
Although modification of tumor cells in vitro with Flt3L-expressing vectors could also generate immunogenic tumor cells, the current studies are still insufficient in supporting that the modified tumor cells in this manner can serve as therapeutic vaccines to treat established large tumors. 16 Moreover, techniques used in the previous experiments was in vitro gene transferring approaches, which were mediated with retroviral vectors and could not be efficiently used for in vivo gene delivery. It is urgently to be known if local high concentration of Flt3L proteins produced by tumor cells modified with intratumoral gene transfer procedure can effectively stimulate host immune response to cure established tumors and prevent subsequent tumor challenge and recurrence.
To further investigate efficacy of intratumoral Flt3L gene modification in eliciting host immunity and in treating established tumors, we have developed a recombinant adenoviral vector with an insert of gene encoding extracellular domain of mouse Flt3L proteins. As a control, an adenovirus vector-carrying gene encoding green fluorescent protein (Ad-GFP) was also constructed for monitoring efficacy of infection, both in vitro and in vivo. The results have shown that the immunogenic activity of adenovirus vector-expressing mFlt3L, which is intratumoral injected to mice bearing tumors is significantly stronger than that of Ad-mFlt3L, which were systemically admitted. Neither local nor systemic injection of Ad-GFP was effective in protecting animals from parental tumor challenge. In addition, systemic administration of either Ad-mFlt3L or soluble Flt3L fusion protein was also insufficient in eradicating the established hepa 1-6 heaptoma. These data further support the development of Ad-mFlt3L and modification of tumor cells locally by intratumoral administration as an effective immunogenetherapy for treatment of cancers.
Materials and methods

Animals and tumor cell lines
Ten-to 12-week-old C57BL/6 mice were obtained from the Planned Parenthood Research Institute, Shanghai, People's Republic of China. All animals in this study were housed in pathogen-free conditions and were maintained in accordance with guideline of the Committee on Animals of the Second Military Medical University. Hepa 1-6 cell line is a chemical-induced liver carcinoma cell line derived from C57BL/6 mice. EL4, a lymphoma cell line and SMCC-1, a colon carcinoma cell line, also derived from C57BL/6 mice and an NK-sensitive YAC-1 cell line were purchased from American Tissue Culture Collection (ATCC, Manassas, VA). These cell lines were maintained at 371C in a 5% CO 2 incubator and grown in minimal essential medium (DMEM) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% (v/v) heat-inactivated fetal calf serum that was purchased from Life Technologies (Grand Island, NY). The human embryonic renal cell line, 293, which was engineered to provide E1 gene products of an adenoviral vector, was obtained from ATCC and was maintained in complete medium at 371C in a 5% CO 2 atmosphere for construction of adenovirus vectors.
Construction of recombinant adenovirus vectors
The recombinant adenovirus carrying murine Flt3 ligand (Ad-mFL) was constructed and purified using the procedures described previously. 17 Briefly, pBluescript/ mFlt3L containing the murine Flt3 ligand (mFL) has an insertion of extron 6, encoding only the soluble isoform of mFL. A 790-bp PCR product was digested and cloned into pShuttle-cytomegalovirus (CMV) and sequenced to confirm the identity of mFL cDNA. Then, it was subcloned into the pAdTrack-cytomegalovirus (CMV) shuttle vector. This vector carries GFP reporter, facilitating the efficiency analysis of the following transfection and infection procedure. Homologous recombination of PmeI-linearized pAdTrack-mFL DNA with the viral backbone vector pAd-Easy-1 was completed in Escherichia coli BJ5183 cells, generating replication-defective adenoviral vector. The adenoviruses vector Ad-GFP, identical with Ad-mFL, except insertion of transgene, was constructed by a similar procedure. Ad-mFL and Ad-GFP were propagated in 293 cells and purified by one-step CsCl gradient centrifugation. After dialysis at 41C against 10 mM Tris/HCl (PH 7.5), 1 mM MgCl 2 , and 10% glycerol, aliquots of the vectors were stored at À801C. The titers of the vectors were assessed on 293 cells by intensity of GFP expression. Potential contamination of the viral preparation by wild-type virus was detected by PCR.
Infection with recombinant viruses in vitro
Hepa 1-6 cells (10 5 cells/well) in six-well plates were infected with either Ad-mFL or Ad-GFP at different multiplicity of infections (MOIs), ranging from 10 to 500. The infection efficiency was determined at 48th hour following infection by scoring the number of cells expressing GFP under fluorescence microscope among 200 cells each on replicate wells. To determine the growth of infected cells in vitro, hepa 1-6 cells were seeded into six-well culture plates at a number of 10 4 cells/well and allowed them to adhere to the plate. Then, culture medium was aspirated from each well at 24th hour and the cells were infected with Ad-mFL and Ad-GFP at a MOI of 100 diluted in infection media (DMEM plus 2% fetal bovine serum (FBS)). Cells were incubated at 371C for 60 minutes with a brief agitation every 5 minutes and then, infection medium was replaced with 2 ml of complete medium. Triplicate dishes of each treatment were counted at 2-day intervals until the 14th day after infection.
Determination of transgene expression and production of mFlt3L protein in vitro Hepa 1-6 cells were seeded into six-well plates (5 Â 104/ well) with complete medium and then, infected with AdmFL or Ad-GFP at a MOI of 100 as described previously.
The culture supernatants were collected at the 48th hour following infection for measuring soluble mFL by ELISA according to the manufacturer's protocol (R&D Systems, Minneapolis, MN). At the same time, the cells were harvested and the total RNA was isolated using TRIzol (Life Technologies, Grand Island, NY). cDNA was synthesized at 421C 1 hour from 1.0 mg of RNA, using a (dT) 18 primer, SUPERSCRIPTII(Life Technologies, Grand Island, NY). PCR reactions were performed in a Geneamp 2400 thermocycler (Perkin-Elmer, Foster City, CA) using Expand TM High Fidelity PCR System (Boehringer Mannheim, Mannheim, Germany). The reaction mixture for PCR contained 0.2 mM of each dNTP, 0.5 mM of each primer, 2.5 mM MgCl 2 , variable amounts of cDNA, 3 Unit Expandt Taq polymerase and provided buffer. Reaction cycles consisted of 20 seconds at 941C, 30 seconds at 601C and 60 seconds at 721C. Cycles were preceded by 2 minutes of denaturation at 941C followed by 5 minutes of elongation at 721C. The PCR product was subjected to electrophoresis on a 1.5% agarose gel.
Treatment of established tumors in vivo
Hepa 1-6 cells and Ad-mFL-transfected hepa 1-6 cells in exponential growth phase were harvested by a brief treatment with 0.25% trypsin and 0.02% EDTA, and then resuspended at the concentration of 2 Â 10 7 /ml in PBS. Cell viability was determined by trypan blue exclusion assay, only single-cell suspensions with a viability exceeding 90% were used. 2 Â 10 6 cells in a volume of 100 ml of PBS were inoculated subcutaneously into the right lateral flank of syngenic C57BL/6 mice. When the tumors reached 5-7 mm in diameter (10 days after inoculation), 1 Â 10 9 expression-forming unit (efu) of Ad-mFL or Ad-GFP, diluted in 0.1 ml saline buffer (PBS) or PBS alone were intratumoral injected three times (day 1, 3 and 5). The tumor size in two perpendicular diameters was measured with precision calipers every 3 days. Tumor volume was calculated. Nonpalpable lesions were considered eradicated. Each experiment was repeated three times. Animals showing severe distress or with tumors that exceeded 1.5 cm in two perpendicular diameters or 2 cm in one diameter were killed as requested by Animal Committee of The University. To determine long-term immunity, mice treated with Ad-mFL with the specific rejection of hepa 1-6 tumor challenge were maintained for 2 months. The animals were divided into two groups and rechallenged with 2 Â 10 6 parental hepa 1-6 cells or EL4 cells, respectively. Tumor development was determined by visual observation. Mice treated with Ad-GFP vectors were used as the control group.
Generation of CTLs and cytotoxicity assay
For generation of tumor-specific CTLs, the naı¨ve and treated mice were killed and the spleen was removed aseptically by a routine surgical procedure and single-cell suspensions were prepared by passing spleen tissue mechanically through mesh screens. The purified spleen cells were cocultured with g-irradiated (5000 rad) hepa 1-6 cells and Ad-mFL-transfected hepa 1-6 cells for 9 days in complete RPMI-1640 medium supplemented with 10% FBS, 1% L-glutamine and 20 mm/ml recombinant IL-2. The cytotoxic activity of splenocytes from treated and untreated animals was determined using the 51 Cr release assay. NK cell killing activity was measured by a standard procedure as reported previously. 18 
Adoptive transfer of CTLs and immunodeletion of T cell and NK cells
For the adoptive transfer experiments, the 2 Â 10 7 CTLs were injected intravenously into groups of naı¨ve mice. On the 7th day following adoptive transfer of splenocytes, the animals were challenged by subcutaneous injection either with 2 Â 10 6 parental hepa 1-6 cells or 2 Â 10 6 EL-4 cells into the right flank. Tumor developments were monitored daily and on the 60th day following tumor inoculation, all mice were histopathologically examined for tumor formation in different organs. For depletion experiments, groups of mice were treated with purified rat monoclonal antibodies (Abs) to mouse CD4 (GK1.5), CD8 (Lyt2), NK cells (4D11) or a control rat monoclonal antibody to IgG1 (4G6). Each animal received 500 mg of purified antibody intravenously twice per week for 2 weeks. Two days before the injection of tumor cells, peripheral blood lymphocytes were obtained from individual treated mouse and stained with antibodies to CD4 þ , CD8 þ T cell and NK cells to verify the depletion of these cells. Mice with 90% depletion of these cells were used for the experiments.
ELISpot assay
Spleen cells from each treated or control animal were cocultured in 96-well plates at 2 Â 10 5 cells/well with Ad-mFL transfected, Ad-GFP transfected, parental hepa 1-6 cells or EL-4 cells at 2 Â 10 4 cells/well. Antibodies specific to IFN-g (R4-6A2) and IL-4 (11B11) were purchased from BD Pharmingen, San Diego, CA and used as capture antibodies. The cytokine-secreting cells were visualized with 1 mg/ml biotinylated second antibodies to IFN-g or IL-4 (Jackson ImmunoResearch Lab., West Grove, PA) followed by incubation with alkaline phosphatase-conjugated avidin (Extravidin, Sigma, St Louis, MO) and Western Blue Substrate (Promega, Madison, WI). The numbers of sport-forming cells was determined by an automatic ELISpot analysis system. The total number of spots was determined and the frequency of cytokine-secreting cells was calculated as an average number of spot-forming cells after subtraction of the number of sports from wells containing EL-4 cell cultures.
Immunohistochemistry
Tissue were obtained from the different group of mice and fixed with 10% buffered formalin. After embedding in paraffin, 4 mm section on paraffin-embedded tissue were cut and stained with hematoxylin and eosin. Finally, the sections were routinely examined under a microscope. For immunohistochemical staining, tumor tissues were embedded in Tissue-Tek OCT compound and frozen in Enhancement of antitumor immunity with Flt3 ligand H Wang et al liquid nitrogen. Tissues were sectioned on a cryostat at 5-7 mm and fixed in prechilled acetone for 10 minutes. After rinsing in PBS, endogenous peroxidase activity was quenched with 3% hydrogen peroxide in methanol (v/v) and the slides were rinsed again in PBS. Nonspecific binding was blocked by incubation in PBS containing 1% BSA and 1.5% normal goat serum for 20 minutes. Subsequently, monoclonal antibodies to mouse CD4 þ , CD8
þ , NK cells and isotype-matched control antibody at a dilution of 1:100 with PBS were added to tissues for 1 hour at room temperature within a humidified chamber. After two washes in PBS, the sections were incubated with peroxidase-conjugated anti-rat IgG secondary antibody for 30 minutes. Diaminobenzidene were applied as substrate for the peroxidase reaction and color reaction was developed for 6 minutes. Slides were counterstained with Mayer's hematoxylin and images were digitized using a Sony Imager for data analysis.
Results
Expression of mFL protein in Ad-mFL-infected tumor cells in vitro
We constructed a replication-defective adenoviral vector harboring soluble isoform of mFL. The titer of Ad-mFL and Ad-GFP were 8.4 Â 10 11 efu/ml, and 6.2 Â 10 11 efu/ml, respectively. The efficiency of adenovirus gene transfer in hepa 1-6 cells was determined by measuring reporter gene expression (GFP) 48 hours after infection with Ad-mFL at different MOIs. The transduction efficiency was presented by the percentages of green cells seen under fluorescence microscope. The transduction efficiency of hepa 1-6 at 10 MOI was 5%, and the efficiency increased with high MOIs, reaching 62% at 100 MOI, 95% at 500. Ad-GFP had a similar efficiency. The transduction efficiency at 100 MOI was used in the following experiment. The possibility that viral infection and mFL expression had any direct cytotoxic or cytostatic effects on the hepa 1-6 tumor cells was evaluated by infecting these cells with Ad-mFL at 100 MOI. There are no effects on cell growth or cell viability of Ad-mFL infection compared with that of Ad-GFP or mock infected hepa 1-6 cells. These data showed that the Ad-mFL infection did not have any influence on the growth rates of hepa 1-6 cells in vitro.
We further tested the activity of this virus by infecting hepa 1-6 cells. The mFL transcription and expression of protein were detected in Ad-mFL-infected cells both in vitro and in vivo, but not in Ad-GFP-infected cells by RT-PCR and western blotting (Fig 1a, b) . At the 48th hour, the level of mFL protein production in culture supernatants by the cells infected with Ad-mFL or by the cells from tumors of the treated animals was 80.5 and 78.2 ng/ml separately, which was determined by ELISA. The results indicated that Ad-mFL was able to effectively infect hepa 1-6 cells both in vitro and in vivo which contribute to the expression of transgene and production of mFL. 
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Antitumor activity elicited by Ad-mFL administration in vivo
To explore whether Ad-mFL had therapeutic effects against established tumors in vivo, the hepa 1-6 cell line was subcutaneously injected into syngenic C57BL/6 mice as reported previously. 19 On day 10, mice with nodules ranging from 5 to 7 mm in diameter were injected with 10 9 efu of Ad-mFL, Ad-GFP (a control adenovirus) or saline buffer (PBS). As shown in Figure 2a , a potent antitumor therapeutic effect of Ad-mFL against hepa 1-6 cells-derived tumors was observed. In contrast, treatment with control vector has no effect on the tumor progression. Under such conditions, Ad-mFL induced regression of malignant tumors in five of 20 mice at day 22, and led to complete eradication in all animals at 40 days after Ad-mFL administration. There was no tumor recurrence in 20 tumor-disappearing mice during the extended 180 days observation. In Ad-GFP treatment group, only one out of 10 animals had tumor regression at day 32 and the others developed large tumors and died within 40 days. No tumor-bearing animals survive more than 40 days in all of the control groups. Administration of Ad-mFL can greatly prolong the survival time of the treated animals compared with the control group. Experiments were repeated three times with similar results (Fig 2b) . These results suggest that antitumor activity could be generated by local injection of Ad-mFL, which is predominant mediated by mFL expression of infected tumor cells.
The inhibition of tumor growth is accompanied by a mononuclear cell infiltration in tumor tissue. Microscopic examination of hemotoxylin-and eosin-stained paraffinembedded tumor sections showed the hemorragic necrosis in tumors treated with Ad-mFL that were absent in tumor nodules receiving control adenovirus or saline buffer. The majority of infiltrating cells in Ad-mFL-treated tumors were DCs, NK cells and CD4 þ cells indicated by Immunohistochemistry (data not shown).
Specificity of antitumor immunity for parental tumor rechallenging
To determine whether Ad-mFL treatment of tumorbearing mice promotes the generation of memory antitumor immune responses, we rechallenged C57BL/6 mice that had rejected hepa 1-6 tumor after Ad-mFL treatment. This second tumor challenge was performed in the left lateral flank with 2 Â 10 6 parental hepa 1-6 cells or EL4 cells and SMCC-1 cells (unrelated control), respectively, on the 60th day after the initial tumor rejection. Hepa 1-6 tumor failed to grow in all of the animals, whereas the SMCC-1 and the EL4 tumors grew progressively with a similar speed as the control group, thereby demonstrating the immunological specificity of a longlasting antitumor immune response against hepa 1-6 tumor in the animals with tumor rejection following Ad-mFL administration. In the proliferation and killing experiments in vitro, the splenocytes from mice treated with Ad-mFL showed significantly higher T-cell proliferation responses to irradiated hepa 1-6 cells as compared to splenocytes from Ad-GFP and control mice (Fig 3a) . The majority of stimulated splenocytes are CD3 þ CD4 þ T cells indicated by flowcytometry analysis. When irradiated EL-4 cells were used as the stimulators, no proliferative responses were observed. In a parallel experiment, splenocytes from treated animals had a significantly killing activity to both Ad-mFL transfected hepa 1-6 cells and untransfected hepa 1-6 cells as well as a YAC-1 cell line, but not to unrelated tumor cells (Fig 3b) .
Abrogation of antitumor immunity by depletion of T cells or NK cells
To investigate the role of cellular components in the regression of tumor, we injected naı¨ve mice with the antibodies to remove the respective cell populations. After 14 days, when flowcytometry analysis of peripheral and spleen cells from antibody-injected animals showed that þ T cells and NK cells was unable to completely block tumor regression, although tumors grew more rapidly in the mice than that in the animals with a deletion of either CD4 þ T cells or NK cells (Fig 4) . The findings are different from those obtained in similar experiments with a breast carcinoma model for which CD4 þ T cells are not required for tumor rejection. 16 The specificity of antitumor immunity was also assessed with ELISpot assays, which revealed a significantly higher frequency of IFN-g producing cells, but not IL-4-secreting cells in the mice treated with Ad-mFL, as compared to the Ad-GFP and PBS controls (Fig 5) . In a comparable study, the nature of the frequency of IFN-g T cells in the spleen cells from the treated animals, which were restimulated in vitro with either parental hepa 1-6 or Ad-mFL-transfected cell lines, was further determined. The proliferation profile of both IFN-g and IL-4-secreting T cells in the spleen cells restimulated with untransfected hepa 1-6 cells was similar with that in the spleen cells restimulated with Ad-mFL transfected hepa 1-6 cells. These results suggest that specific immunity against hepa 1-6 tumor cells induced by intratumoral injection of Ad-mFL is in part mediated by IFN-g secreting T cells (Type 1). The resulting immunity elicited by this approach is specific for both parental and transfected tumor cell lines, which may be a key element for tumor regression.
Systemic splenocytes adoptive therapy
To investigate whether elicited antitumoral immunity could be adoptively transferred to naı¨ve animals by infusion of spleen T cells from the treated animals, T-cell cultures were obtained from the spleen of mice that had rejected hepa 1-6 cells tumors upon intratumoral injection of Ad-mFL by 7-day coculture with mitomycin-C-treated hepa 1-6 cells. Such short-term T-cell cultures might contain both activated CD4 þ and CD8 þ T cells as well as NK cells, as previously reported. 20 Adoptive transfer of 5 Â 10 7 of such T cells showed significant effect [21] [22] [23] [24] Tumor vaccines generated by transfection of immune-regulating molecules in vitro are also effective as a therapeutic vaccine in generating host immune response against tumors in various models. 22 Although all of these strategies are effective in inhibiting tumor growth in experimental animal models, all require the target cells to be removed from the body, manipulated ex vivo, and returned to the tumor-bearing donor/recipient. 21, 23, 25, 26 We now demonstrate that intratumoral injection of Ad-mFL causes the rejection of transplanted hepa 1-6 hepatoma in a syngenic model. The Ad-mFL that was constructed and used in this experiment is highly efficient in infecting tumor cells both in vitro and in vivo. The tumor cells infected by local injection procedure showed a similar production level of mFL as compared to that infected in vitro. This suggests that the local delivery of Ad-mFL might be an alternative for genetically modifying tumor cells to stimulate host immune responses, which is more simple and has a broad implication in modification of tumor cells in vivo.
Administration of soluble FL protein showed potent therapeutic efficacy in promoting tumor regression in several tumor models, including fibrosarcoma, 7 melanoma, lymphoma, 27 breast cancer, 14,15 leukemia 13 and prostate cancer, 28 though complete regression was rarely obtained in these tumor models. This biological activity was partially associated with serum level of soluble FL protein that led to proliferation and activation of NK cells and DCs. Our previous reports showed that the mouse colon carcinoma cell line, when transfected with hu-FL gene in vitro became immunogenic and could be used for vaccine to prevent tumor cell challenge. 16 However, the FL gene in these experiments was of human origin and this makes the data hard to interpret because several human antigens, such as melanoma antigen p97, have been shown to increase their immunogenicity. 22 Rejection of transplanted tumors mediated by local injection of Ad-mFL is more effective than that induced by vaccination with tumor cells transfected with hu-FL or m-FL genes in vitro. In syngenic animal models, vaccination with in vitro-modified tumor cells producing FL protein only temperately inhibited tumor growth and tumor development and recurrence occurred when treatment ends, especially in poorly immunogenic tumor models. 28 In this report, we showed that injection of Ad-mFL was able to completely reject established tumors in almost all of mice. The injected animals were found to Figure 5 Frequency of IFN-g-secreting cells in the splenocytes from the tumor bearing animals treated with Ad-mFL, Ad-GFP and PBS. Mice bearing hepa 1-6 tumors were treated with intratumoral injection of Ad-mFL, Ad-GFP and PBS. At 2 weeks after final injection, mice were killed and single-cell suspensions of splenocytes were prepared. After coculturation with hepa 1-6 cells in vitro for 48 hours, the frequencies of IFN-g and IL-4-producing cells were determined by ELISpot assay and results were reported as mean7SEM. Figure 6 Prevention of hepa 1-6 tumor challenge in mice adoptively infused with splenocytes from the mice with tumor regression following treatment. Groups of C57BL/6 naïve mice were intravenously infused with 5 Â 10 7 splenocytes prepared from the spleens of mice with rejected tumors and were restimulated in vitro with mitomycin-C-treated hepa 1-6 cells for 7 days. After 1 week following splenocyte transfusion, mice were challenged subcutaneously with 2 Â 10 6 hepa 1-6, EL-4 and SMCC-1 cells individually. Tumor growth and animal survival was measured and calculated. þ and NK cells are necessary for the rejection of tumors in this model system. Present data is different from the results we obtained in another mouse tumor model, which was treated with hu-FL gene-modified tumor vaccines. 16 The explanation for this difference may be contributed to the expression of different rejection antigens on these tumors.
We have demonstrated that an intratumoral injection of Ad-mFL induces a systemic immune response to hepa 1-6 hepatoma that has both memory and specificity. In contrast, injection of control vectors without an insert of mFL was unable to stimulate host response for rejection of tumors. Animals with tumor regression following the treatment procedure were specifically protected against parental tumor challenge but were not protected against challenge with EL-4 cells, a syngenic lymphoma cell line. In vivo data is consistent with the in vitro data showing that splenocytes from mice treated with Ad-mFL proliferated vigorously in vitro when both Ad-mFL-modified and parental hepa 1-6 cells were used as stimulators. No proliferating responses were observed when EL-4 cells were used as stimulators. The majority of responder splenocytes was CD4 þ T cells, which produced IFN-g in ELISpot assay indicating a Th 1 response was induced. However, repeated attempts to detect a CTL response failed. These data suggest that immunity elicited by this approach is tumor-specific and mainly mediated by CD4 þ T cells. The enhancement of tumor-specific immunity may be partly due to the local recruitment of DCs to the injection site, which could then uptake and present tumor antigen to T cells and elicit an antigenspecific antitumor immunity. This hypothesis is strongly supported by a majority infiltration of DCs in tumor tissues in treated animals but not in that in vector control animals. More importantly, this antigen-specific immunity is long-lasting and could be detected after 6 months following the treatment, which could be also transferred into naı¨ve animals successfully, by adoptively transferring spleen cells from the treated animals. The explanation for this effectively adoptive transferring may be associated with CD4 þ memory T cells and DCs in the transferred spleen cells, which has been sensitized and presented with the tumor antigens on their cell surfaces. When these cells were adoptively transferred into naı¨ve animals, the functioning memory T cells and DCs could expend in the animals and directly involve immune response against tumor challenge by the well-defined mechanisms reported previously. 29, 30 Our data thus indicate that an antitumor immune response can be elicited by intratumoral injection of Ad-mFL vector. Thus, in addition to the simplicity and potential clinical expediency, this in vivo approach might provide a novel strategy for treatment of liver cancer.
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